Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the
reliable data of third-line treatment for non-small cell lung cancer, the investigators
designed a clinical study of anlotinib in maintenance therapy for advanced NSCLC to
prospectively evaluate the efficacy of anlotinib in maintenance therapy for advanced NSCLC.
Value, to provide a scientific basis for prolonging the survival time of patients with
advanced NSCLC, improving the quality of life of patients in the course of treatment, and
optimizing treatment strategies to a greater extent.
Phase:
N/A
Details
Lead Sponsor:
First Hospital of Jilin University The First Hospital of Jilin University